Q-omics provides the consensus-scored NF1P6 profile across patient tissues and cancer cell-line models. NF1P6 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NF1P6 is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, NF1P6 RNA expression shows 5,733 significant gene co-expression associations, with the highest sampling consensus in HNSC. Together, these results highlight KICH, PRAD, and HNSC as cancer lineages where NF1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NF1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NF1P6 survival associations across molecular data types. NF1P6 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NF1P6 RNA expression–survival associations across cancer types. High NF1P6 expression shows unfavorable associations in KICH, BRCA, DLBC, PCPG, KIRC and BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for NF1P6 RNA expression.
This table summarizes NF1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for NF1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NF1P6 shows higher tumor expression in PRAD. The PRAD box plot shows higher NF1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.110, t-test p = .017).
This table shows molecular features associated with NF1P6 in patient tissues and cancer cell lines. In patient samples, NF1P6 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
